文献速递肿瘤 PET/CT

68Ga-PSMA-11与18F-rhPSMA-7 PET/CT配对比较:非肿瘤性摄取频率与肿瘤阳性率

Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity.
PubMed 文献 · J Nucl Med · 2020-12-04

该回顾性配对研究比较了160例18F-rhPSMA-7与160例68Ga-PSMA-11 PET/CT(初诊分期33例、生化复发127例)中非肿瘤性摄取与肿瘤阳性情况。两种示踪剂肿瘤阳性率均较高,但18F-rhPSMA-7的非肿瘤性摄取更多,而局部复发和初诊前列腺癌的肿瘤/膀胱比值显著更高。

要点

  • 两种示踪剂肿瘤阳性率均较高,初诊前列腺癌全部阳性。
  • 18F-rhPSMA-7非肿瘤性摄取更多(67.0% vs 34.6%)。
  • 18F-rhPSMA-7肿瘤/膀胱比值显著高于68Ga-PSMA-11。

核心结论

  • 68Ga-PSMA-11与18F-rhPSMA-7的肿瘤阳性率均持续较高,但18F-rhPSMA-7的非肿瘤性摄取更频繁。
  • 经培训的医师结合形态学影像和已知PSMA陷阱可可靠识别良性摄取。
  • 配对比较本身可能引入偏倚。

研究设计与样本

  • 回顾性配对比较研究,将160例18F-rhPSMA-7与160例68Ga-PSMA-11 PET/CT按临床特征配对(初诊分期33例、生化复发127例)。
  • 由两名核医学医师审阅所有扫描,先识别PET阳性病灶,再区分前列腺癌可疑病灶与良性病灶。
  • 分别记录每个区域PSMA配体摄取最高病灶的SUVmax,并分别比较两种示踪剂的SUVmax。

主要发现

  • 18F-rhPSMA-7与68Ga-PSMA-11分别显示566个和289个PSMA配体阳性病灶,其中379个(67.0%)和100个(34.6%)被认为良性。
  • 良性病灶病因分布相似:神经节、骨、非特异性淋巴结在18F-rhPSMA-7为42%、24%、25%,在68Ga-PSMA-11为32%、24%、38%。
  • 初诊前列腺癌两种示踪剂均全部阳性(各33例),68Ga-PSMA-11在两个疾病阶段观察到的转移灶略多(18F-rhPSMA-7为113个,68Ga-PSMA-11为124个)。
  • 局部复发或初诊前列腺癌中两种示踪剂SUVmax无差异(P > 0.05)。
  • 肿瘤/膀胱比值在18F-rhPSMA-7显著更高:局部复发为4.9 ± 5.3 vs. 2.2 ± 3.7(P = 0.02),初诊前列腺癌为9.8 ± 9.7 vs. 2.3 ± 2.6(P < 0.001)。

关键数值与推荐

  • 18F-rhPSMA-7与68Ga-PSMA-11的PSMA阳性病灶中良性比例分别为67.0%和34.6%。
  • 局部复发肿瘤/膀胱比值4.9 ± 5.3 vs. 2.2 ± 3.7,P = 0.02。
  • 初诊前列腺癌肿瘤/膀胱比值9.8 ± 9.7 vs. 2.3 ± 2.6,P < 0.001。

临床怎么用

  • 阅片时应结合CT形态学信息并警惕已知PSMA陷阱,以区分良性摄取与肿瘤。
  • 充分的阅片培训有助于利用18F-rhPSMA-7在物流和临床上的优势。
  • 18F-rhPSMA-7较高的肿瘤/膀胱比值可能有利于前列腺床病灶的评估。

局限性

  • 配对比较设计可能引入偏倚。
  • 为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of prostate cancer theranostic agents. 18F-rhPSMA-7 offers the advantages of 18F labeling and low urinary excretion compared with 68Ga-PSMA-11. Here, we compare the frequency of non-tumor-related uptake and tumor positivity with 68Ga-PSMA-11 and 18F-rhPSMA-7 in patients with primary or recurrent prostate cancer. Methods: This retrospective matched-pair comparison matched 160 18F-rhPSMA-7 with 160 68Ga-PSMA-11 PET/CT studies for primary staging (n = 33) and biochemical recurrence (n = 127) according to clinical characteristics. Two nuclear medicine physicians reviewed all scans, first identifying all PET-positive lesions and then differentiating lesions suggestive of prostate cancer from those that were benign, on the basis of known pitfalls and ancillary information from CT. For each region, the SUVmax of the lesion with the highest PSMA ligand uptake was noted. Tumor positivity rates were determined, and SUVmax was compared separately for each tracer. Results:18F-rhPSMA-7 and 68Ga-PSMA-11 PET revealed 566 and 289 PSMA ligand-positive lesions, respectively. Of these, 379 and 100 lesions, equaling 67.0% and 34.6%, respectively, of all PSMA-positive lesions, were considered benign. The distribution of their etiology was similar (42%, 24%, and 25% with 18F-rhPSMA-7 vs. 32%, 24%, and 38% with 68Ga-PSMA-11 for ganglia, bone, and unspecific lymph nodes, respectively). All primary tumors were positive with both agents (n = 33 each), whereas slightly more metastatic lesions were observed with 68Ga-PSMA-11 in both disease stages (113 for 18F-rhPSMA-7 and 124 for 68Ga-PSMA-11). The SUVmax of 18F-rhPSMA-7 and 68Ga-PSMA-11 did not differ (P > 0.05) in local recurrence or primary prostate cancer; however, the tumor-to-bladder ratio was significantly higher with 18F-rhPSMA-7 (4.9 ± 5.3 vs. 2.2 ± 3.7, P = 0.02, for local recurrence; 9.8 ± 9.7 vs. 2.3 ± 2.6, P < 0.001, for primary prostate cancer). Conclusion: The tumor positivity rate was consistently high for 68Ga-PSMA-11 and 18F-rhPSMA-7. Both tracers revealed a considerable number of areas of uptake that were reliably identified as benign by trained physicians making use of corresponding morphologic imaging and known PSMA pitfalls. These were more frequent with 18F-rhPSMA-7. However, the matched-pair comparison could have introduced a source of bias. Adequate reader training can allow physicians to differentiate benign uptake from disease and be able to benefit from the logistical and clinical advantages of 18F-rhPSMA-7.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kroenke M, Mirzoyan L, Horn T, et al. Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non-Tumor-Related Uptake and Tumor Positivity. J Nucl Med. 2020. PMID: 33277394. doi:10.2967/jnumed.120.251447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。